Recombinant LFNG antibody

Catalog No. ABIN7881470

The Rabbit Monoclonal anti-LFNG antibody (Clone 31L39) (ABIN7881470) specifically detects LFNG in WB, IF and ICC. The antibody is reactive with Human, Mouse and Rat samples.

Quick Overview for Recombinant LFNG antibody (ABIN7881470)

Target: LFNG (LFNG O-Fucosylpeptide 3-beta-N-Acetylglucosaminyltransferase (LFNG))

Antibody Type: Recombinant Antibody

Reactivity: Human, Mouse, Rat

Host: Rabbit

Clonality: Monoclonal

Conjugate: This LFNG antibody is un-conjugated

Application: Western Blotting (WB), Immunofluorescence (IF), Immunocytochemistry (ICC)

Clone: 31L39

Product Details anti-LFNG Antibody

Purpose: LFNG Antibody / Lunatic Fringe

Purification: Affinity-chromatography

Immunogen: A synthesized peptide derived from human Lunatic Fringe was used as the immunogen for the LFNG antibody.

Isotype: IgG

Application Details

Application Notes: Optimal dilution of the LFNG antibody should be determined by the researcher.

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Rabbit IgG in phosphate buffered saline, pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol, 0.4-0.5 mg/mL BSA

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Store the LFNG antibody at -20oC.

Target Details for LFNG

Target: LFNG (LFNG O-Fucosylpeptide 3-beta-N-Acetylglucosaminyltransferase (LFNG))

Alternative Name: LFNG

Background: LFNG antibody detects lunatic fringe, a glycosyltransferase that modifies Notch receptors and regulates Notch signaling pathways. LFNG belongs to the fringe family of glycosyltransferases, which add N-acetylglucosamine residues to O-fucose on epidermal growth factor-like repeats of Notch. This modification alters ligand binding specificity and modulates signaling outcomes critical for development and tissue homeostasis.

Research using LFNG antibody has highlighted the protein's role in embryogenesis. LFNG is required for somitogenesis, the process that establishes segmented structures in the developing embryo. Loss of LFNG function leads to defects in somitic patterning and skeletal abnormalities, demonstrating its importance in developmental timing. Beyond embryonic segmentation, LFNG also contributes to hematopoiesis, vascular development, and neural differentiation by fine-tuning Notch signaling activity.

Dysregulation of LFNG has been implicated in cancer and congenital disorders. Aberrant expression of LFNG can lead to uncontrolled Notch signaling, a hallmark of various malignancies including breast cancer and T-cell acute lymphoblastic leukemia. Reduced LFNG activity may also contribute to congenital scoliosis and vertebral malformations. Understanding how LFNG modifies Notch receptors provides insights into therapeutic targeting of developmental and cancer-related pathways.

Antibodies against LFNG are validated for western blot, immunohistochemistry, and immunofluorescence. These tools enable researchers to study expression patterns in embryonic and adult tissues, as well as to evaluate changes in Notch pathway regulation. Clone-based antibodies ensure reliable detection of LFNG across experimental conditions.

NSJ Bioreagents provides this LFNG antibody for developmental biology, cancer, and signaling research.

UniProt: Q8NES3

Pathways: Notch Signaling